

Compléments à l'article « Marquage isotopique des médicaments et des nanoparticules », S. Feuillastre *et coll.* (*L'Act. Chim.*, 2021, 460-461, p. 137)

Figure A1

Marquage de thioéthers à l'aide de Ru/C et d'anilines catalysé par des particules d'iridium (IrNp).




Figure A2

Marquage au carbone d'urées en une étape à partir du $[^{13}\text{C}]\text{CO}_2$, $[^{14}\text{C}]\text{CO}_2$ et $[^{11}\text{C}]\text{CO}_2$. * = conversion radiochimique.




Figure A3

Marquage au carbone 14 d'acides carboxyliques à partir du $[^{13}\text{C}]\text{CO}_2$ et $[^{14}\text{C}]\text{CO}_2$ par échange isotopique.





Figure A4

Marquage au carbone 14 d'acides carboxyliques par échange isotopique à partir du $[^{14}\text{C}]\text{CO}_2$ (a) et du $[^{14}\text{C}]\text{CO}$ (b).



Références

- [1] J.P. Ryan, P.R. O'Connor, The Claisen rearrangement of phenyl allyl ethers, labeled with carbon-14, *J. Am. Chem. Soc.*, **1952**, 74, p. 5866-69.
- [2] J.D. Roberts, H.E. Simmons, L.A. Carlsmith, C.W. Vaughan, Rearrangement in the reaction of chlorobenzene-1- C^{14} with potassium amide¹, *J. Am. Chem. Soc.*, **1953**, 75, p. 3290-91.
- [3] a) J. Atzrodt, V. Derda, W.J. Kerr, M. Reid, Deuterium- and tritium-labelled compounds: applications in the life sciences, *Angew. Chem. Int. Ed.*, **2018**, 57, p. 1758-83; b) W.D. Lehmann, A timeline of stable isotopes and mass spectrometry in the life sciences, *Mass Spec. Rev.*, **2017**, 36, p. 58-85.
- [4] a) E.M. Isin, C.S. Elmore, G.N. Nilsson, R.A. Thompson, L. Weidolf, Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies, *Chem. Res. Toxicol.*, **2012**, 25, p. 532-42; b) N. Penner, L. Xu, C. Prakash, Radiolabeled absorption, distribution, metabolism,

- and excretion studies in drug development: why, when, and how?, *Chem. Res. Toxicol.*, **2012**, 25, p. 513-31; c) N. Penner, L.J. Klunk, C. Prakash, Human radiolabeled mass balance studies: objectives, utilities and limitations, *Biopharm. Drug Dispos.*, **2009**, 30, p. 185-203.
- [5] P.F. Fitzpatrick, Combining solvent isotope effects with substrate isotope effects in mechanistic studies of alcohol and amine oxidation by enzymes, *Biochim. Biophys. Acta*, **2015**, 1854, p. 1746-55.
- [6] M. Shao *et al.*, The isotopic effects of deuteration on optoelectronic properties of conducting polymers, *Nat. Commun.*, **2014**, 5, 3180.
- [7] T.G. Gant, Using deuterium in drug discovery: leaving the label in the drug, *J. Med. Chem.*, **2014**, 57, p. 3595-611.
- [8] H.M. De Feyter *et al.*, Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo, *Sci. Adv.*, **2018**, 4, 7314.

- [9] a) B. Chaudret *et al.*, Ligand-stabilized ruthenium nanoparticles: synthesis, organization, and dynamics, *J. Am. Chem. Soc.*, **2001**, 7584-93; b) P. Lara, O. Rivada-Wheelaghan, S. Conejero, R. Poteau, K. Philippot, B. Chaudret, Ruthenium nanoparticles stabilized by N-heterocyclic carbenes: ligand location and influence on reactivity, *Angew. Chem. Int. Ed.*, **2011**, 50, p. 12080-84.
- [10] a) G. Pieters *et al.*, Regioselective and stereospecific deuteration of bioactive aza compounds by the use of ruthenium nanoparticles, *Angew. Chem. Int. Ed.*, **2014**, 53, p. 230-34; b) C. Taglang *et al.*, Enantiospecific C-H activation using ruthenium nanocatalysts, *Angew. Chem. Int. Ed.*, **2015**, 54, p. 10474-77; c) A. Palazzolo *et al.*, Efficient access to deuterated and tritiated nucleobase pharmaceuticals and oligonucleotides using hydrogen-isotope exchange, *Angew. Chem. Int. Ed.*, **2019**, 131, p. 4945-49; d) V. Pfeifer *et al.*, Hydrogen isotope exchange catalyzed by Ru nanocatalysts: labelling of complex molecules containing N-heterocycles and reaction mechanism insights, *Chem. Eur. J.*, **2020**, 26, p. 4988-96.
- [11] L. Gao *et al.*, Ruthenium-catalyzed hydrogen isotope exchange of C(sp³)-H bonds directed by a sulfur atom, *Chem. Commun.*, **2018**, 54, p. 2986-89.
- [12] M. Valero *et al.*, NHC-stabilized iridium nanoparticles as catalysts in hydrogen isotope exchange reactions of anilines, *Angew. Chem. Int. Ed.*, **2020**, 59, p. 3517-22.
- [13] A. Del Vecchio *et al.*, Late-stage isotopic carbon labeling of pharmaceutically relevant cyclic ureas directly from CO₂, *Angew. Chem. Int. Ed.*, **2018**, 57, p. 9744-48.
- [14] a) D. Audisio, T. Cantat, G. Destro, EP18305407, **2018**, WO 2019/193068 A1; b) G. Destro *et al.*, Dynamic carbon isotope exchange of pharmaceuticals with labeled CO₂, *J. Am. Chem. Soc.*, **2019**, 141, p. 780-84.
- [15] a) C. Kingston *et al.*, Direct carbon isotope exchange through decarboxylative carboxylation, *J. Am. Chem. Soc.*, **2019**, 141, p. 774-79; b) A. Tortajada *et al.*, Catalytic decarboxylation/carboxylation platform for accessing isotopically labeled carboxylic acids, *ACS Catal.*, **2019**, 9, p. 5897-901.
- [16] D.R. Gauthier Jr. *et al.*, Palladium-catalyzed carbon isotope exchange on aliphatic and benzoic acid chlorides, *J. Am. Chem. Soc.*, **2018**, 140, p. 15596-600.
- [17] D. Georgin *et al.*, Preparation of ¹⁴C-labeled multiwalled carbon nanotubes for biodistribution investigations, *J. Am. Chem. Soc.*, **2009**, 131, p. 14658-59.
- [18] B. Czarny *et al.*, Carbon nanotube translocation to distant organs after pulmonary exposure: insights from *in situ* ¹⁴C-radiolabeling and tissue radioimaging, *ACS Nano*, **2014**, 8, p. 5715-24.
- [19] E. Nehlig *et al.*, Using hydrogen isotope incorporation as a tool to unravel the surfaces of hydrogen-treated nanodiamonds, *Nanoscale*, **2019**, 11, p. 8027-36.
- [20] S. Claveau *et al.*, Delivery of siRNA to Ewing sarcoma tumor xenografted on mice, using hydrogenated detonation nanodiamonds: treatment efficacy and tissue distribution, *Nanomaterials*, **2020**, 10, 553.
- [21] a) A. Gaudin *et al.*, Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury, *Nature Nanotech.*, **2014**, 9, p. 1054-62; b) A. Gaudin *et al.*, Pharmacokinetics, biodistribution and metabolism of squalenoyl adenosine nanoparticles in mice using dual radio-labeling and radio-HPLC analysis, *J. Controlled Release*, **2015**, 212, p. 50-58; c) M. Rouquette *et al.*, Squalene-adenosine nanoparticles: ligands of adenosine receptors or adenosine prodrug?, *J. Pharmacol. Exp. Ther.*, **2019**, 369, p. 144-51.
- [22] a) D. Sobot *et al.*, Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery, *Nat. Commun.*, **2017**, 15678; b) D. Sobot *et al.*, Circulating lipoproteins: a Trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells, *Mol. Therapy*, **2017**, 25, p. 1596-605.